Join Claris Biotherapeutics for an event featuring key opinion leader (KOL) John Affeldt, MD (Loma Linda University Health), who will join company management to discuss the unmet need and current treatment landscape for limbal stem cell deficiency (LSCD), a rare blinding disease.

The event will provide an overview of CSB-001 (oremepermin alfa ophthalmic solution), Claris Bio’s lead investigational therapy designed to target the underlying pathophysiology of LSCD. CSB-001 has the potential to provide a transformative treatment option beyond palliative care or surgery for patients with this severe eye disease. These data were presented at a podium presentation at the American Academy of Ophthalmology (AAO) Annual Meeting on October 11, 2026.

A live question and answer session will follow the formal presentations.